Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is always on improving patient outcomes, with integrity as a core value.
You took over as general manager of Lilly´s Swiss affiliate a few months ago, during what is an extremely exciting time for the company globally as David Ricks will be transitioning into his new position as CEO by the new year. What mandate were you set when it comes to developing Lilly´s business in Switzerland?
"In Switzerland, Lilly has an excellent talent base of just over 70 people, allowing us to compete with the largest multinational companies in the country."
